EP1080113A4 - Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance - Google Patents
Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissanceInfo
- Publication number
- EP1080113A4 EP1080113A4 EP99924253A EP99924253A EP1080113A4 EP 1080113 A4 EP1080113 A4 EP 1080113A4 EP 99924253 A EP99924253 A EP 99924253A EP 99924253 A EP99924253 A EP 99924253A EP 1080113 A4 EP1080113 A4 EP 1080113A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- inhibitors
- radiation
- treatment
- growth factor
- factor receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79612 | 1987-07-30 | ||
US206138 | 1988-06-13 | ||
US8561398P | 1998-05-15 | 1998-05-15 | |
US7961298A | 1998-05-15 | 1998-05-15 | |
US85613P | 1998-05-15 | ||
US20613898A | 1998-12-07 | 1998-12-07 | |
PCT/US1999/010741 WO1999060023A1 (fr) | 1998-05-15 | 1999-05-14 | Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1080113A1 EP1080113A1 (fr) | 2001-03-07 |
EP1080113A4 true EP1080113A4 (fr) | 2002-04-17 |
Family
ID=27373511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99924253A Withdrawn EP1080113A4 (fr) | 1998-05-15 | 1999-05-14 | Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1080113A4 (fr) |
JP (1) | JP2002515511A (fr) |
KR (1) | KR20010071271A (fr) |
CN (1) | CN1314917A (fr) |
AU (1) | AU4079999A (fr) |
BR (1) | BR9910511A (fr) |
CA (1) | CA2332331A1 (fr) |
CZ (1) | CZ20004224A3 (fr) |
HK (1) | HK1040720A1 (fr) |
IL (1) | IL139707A0 (fr) |
MX (1) | MXPA00011248A (fr) |
PL (1) | PL348634A1 (fr) |
SK (1) | SK17282000A3 (fr) |
WO (1) | WO1999060023A1 (fr) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1400536A1 (fr) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Procédé pour fabriquer des anticorps humanisés |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
US6417168B1 (en) | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
EP1745799B1 (fr) | 1998-03-04 | 2015-09-02 | The Trustees of The University of Pennsylvania | Compositions et méthodes pour le traitement de tumeurs |
US6706721B1 (en) | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
AU780454B2 (en) | 1999-06-03 | 2005-03-24 | Jessie L.S. Au | Methods and compositions for modulating cell proliferation and cell death |
GB9925958D0 (en) * | 1999-11-02 | 1999-12-29 | Bundred Nigel J | Therapeutic use |
US7087613B2 (en) | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
WO2002011677A2 (fr) * | 2000-08-09 | 2002-02-14 | Imclone Systems Incorporated | Traitement de maladies hyperproliferatives au moyen d'antagonistes du recepteur de facteur de croissance epidermique |
AU2002239486A1 (en) * | 2000-12-08 | 2002-06-18 | Uab Research Foundation | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
CU22979A1 (es) * | 2000-12-08 | 2004-09-09 | Centro Inmunologia Molecular | Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina |
US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
AU2003213687A1 (en) | 2002-03-04 | 2003-09-22 | Imclone Systems Incorporated | Human antibodies specific to kdr and uses thereof |
ES2299692T3 (es) * | 2002-04-02 | 2008-06-01 | Nerviano Medical Sciences S.R.L. | Terapia combinada contra tumores que comprende derivados de distmicina acriloil sustituido y radioterapia. |
US7217796B2 (en) | 2002-05-24 | 2007-05-15 | Schering Corporation | Neutralizing human anti-IGFR antibody |
ES2527871T3 (es) | 2003-05-01 | 2015-02-02 | Imclone Llc | Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana |
CN101966338A (zh) | 2003-06-09 | 2011-02-09 | 塞缪尔·瓦克萨尔 | 用胞外拮抗物和胞内拮抗物抑制受体酪氨酸激酶的方法 |
US7312215B2 (en) | 2003-07-29 | 2007-12-25 | Bristol-Myers Squibb Company | Benzimidazole C-2 heterocycles as kinase inhibitors |
JP4638870B2 (ja) | 2003-08-13 | 2011-02-23 | ファイザー・プロダクツ・インク | 修飾ヒトigf−1r抗体 |
US7326567B2 (en) | 2003-11-12 | 2008-02-05 | Schering Corporation | Plasmid system for multigene expression |
PE20050928A1 (es) | 2003-11-21 | 2005-11-08 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti-igfr1 |
EP1735348B1 (fr) | 2004-03-19 | 2012-06-20 | Imclone LLC | Humain anticorps dirige contre le recepteur du facteur de croissance epidermique |
NZ551431A (en) | 2004-06-03 | 2010-04-30 | Hoffmann La Roche | Treatment with cisplatin and an EGFR-inhibitor |
JP2008521907A (ja) | 2004-12-03 | 2008-06-26 | シェーリング コーポレイション | 抗igf1r治療について患者を予め選択するためのバイオマーカー |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
BRPI0611984A2 (pt) | 2005-06-17 | 2009-07-07 | Imclone Systems Inc | uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo |
JP5055284B2 (ja) | 2005-09-20 | 2012-10-24 | オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー | インシュリン様成長因子−1受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー |
US8236308B2 (en) | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
WO2008022746A1 (fr) | 2006-08-21 | 2008-02-28 | F. Hoffmann-La Roche Ag | Thérapie tumorale avec anticorps anti-vegf |
EP3248617A3 (fr) | 2007-02-16 | 2018-02-21 | Merrimack Pharmaceuticals, Inc. | Anticorps dirigés contre l'erbb3 et leurs utilisations |
MX2009010611A (es) * | 2007-04-03 | 2010-03-26 | Micromet Ag | Enlazadores biespecificos, especificos para especies. |
BRPI0816458A2 (pt) | 2007-09-05 | 2013-03-12 | Hoffmann La Roche | terapia combinada com anticorpos anti-cd20 tipo i e tipo ii |
US20090098118A1 (en) | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
AR071891A1 (es) | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
EP2318548B1 (fr) | 2008-08-15 | 2013-10-16 | Merrimack Pharmaceuticals, Inc. | Procédés, systèmes et produits pour prévoir une réponse de cellules tumorales à un agent thérapeutique, et traitement d'un patient selon la réponse prévue |
WO2010099139A2 (fr) | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Thérapie anti-cancer combinée |
WO2010099137A2 (fr) | 2009-02-26 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Procédés in situ pour surveiller l'état emt de cellules tumorales in vivo |
WO2010107968A1 (fr) | 2009-03-18 | 2010-09-23 | Osi Pharmaceuticals, Inc. | Plurithérapie contre le cancer comprenant l'administration d'un inhibiteur de l'egfr et d'un inhibiteur de l'igf-1r |
TWI461211B (zh) | 2009-03-20 | 2014-11-21 | Genentech Inc | 抗-her抗體 |
EP2236139A1 (fr) | 2009-03-31 | 2010-10-06 | F. Hoffmann-La Roche AG | Thérapie combinée d'erlotinibe avec un anticorps anti-IGF-1R, qui n'inhibe pas la liaison d'insuline dans le récepteur d'insuline |
US20100247484A1 (en) | 2009-03-31 | 2010-09-30 | Heinrich Barchet | Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3 |
TWI409079B (zh) | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化cd20抗體與苯達莫斯汀(bendamustine)之組合療法 |
WO2011018225A1 (fr) | 2009-08-14 | 2011-02-17 | Roche Glycart Ag | Polythérapie à base d'un anticorps afucosylé anti-cd20 et de fludarabine et/ou mitoxantrone |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
AU2011223643A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US20110217309A1 (en) | 2010-03-03 | 2011-09-08 | Buck Elizabeth A | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
SG183532A1 (en) | 2010-03-11 | 2012-09-27 | Merrimack Pharmaceuticals Inc | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
CA2795544A1 (fr) | 2010-04-27 | 2011-11-03 | Roche Glycart Ag | Polytherapie d'un anticorps anti-cd20 afucosyle et d'un inhibiteur de mtor |
TW201208703A (en) | 2010-08-17 | 2012-03-01 | Roche Glycart Ag | Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
CN103261229A (zh) | 2010-12-16 | 2013-08-21 | 罗切格利卡特公司 | 无岩藻糖基化cd20抗体与mdm2抑制剂的联合疗法 |
AU2012212075A1 (en) | 2011-02-02 | 2013-07-18 | Amgen Inc. | Methods and compositons relating to inhibition of IGF-1R |
WO2012116040A1 (fr) | 2011-02-22 | 2012-08-30 | OSI Pharmaceuticals, LLC | Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de la kinase du récepteur du facteur de croissance 1 analogue à l'insuline dans le carcinome hépatocellulaire |
WO2012129145A1 (fr) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Polythérapie du cancer du poumon non à petites cellules (nsclc) |
AU2012239997A1 (en) | 2011-04-07 | 2013-10-17 | Amgen Inc. | Novel EGFR binding proteins |
US9896730B2 (en) | 2011-04-25 | 2018-02-20 | OSI Pharmaceuticals, LLC | Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment |
AU2012335541B2 (en) | 2011-11-11 | 2017-07-06 | Duke University | Combination drug therapy for the treatment of solid tumors |
US20130302274A1 (en) | 2011-11-25 | 2013-11-14 | Roche Glycart Ag | Combination therapy |
BR112014020666A2 (pt) * | 2012-02-23 | 2018-09-25 | U3 Pharma Gmbh | usos de um inibidor de her3 |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
WO2013152252A1 (fr) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Polythérapie antinéoplasique |
CA2884307A1 (fr) | 2012-09-07 | 2014-03-13 | Genentech, Inc. | Therapie combinee d'un anticorps anti-cd20 de type ii et d'un inhibiteur selectif de bcl-2 |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
WO2015100459A2 (fr) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies |
EP3122900A1 (fr) | 2014-03-24 | 2017-02-01 | F. Hoffmann-La Roche AG | Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
PL3319995T3 (pl) | 2015-07-07 | 2019-09-30 | F. Hoffmann-La Roche Ag | Terapia skojarzona z użyciem koniugatu przeciwciało anty-her2-lek i inhibitora bcl-2 |
EA201891304A1 (ru) | 2015-12-03 | 2019-01-31 | Агиос Фармасьютикалс, Инк. | ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ |
US20190015393A1 (en) | 2016-01-18 | 2019-01-17 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | The use of a temporary inhibitor of p53 for preventing or reducing cancer relapse |
CN109415441B (zh) | 2016-05-24 | 2023-04-07 | 英斯梅德股份有限公司 | 抗体及其制备方法 |
WO2019020610A1 (fr) | 2017-07-26 | 2019-01-31 | F. Hoffmann-La Roche Ag | Polythérapie faisant appel à un inhibiteur de bet et à un inhibiteur de bcl-2 |
WO2019020606A1 (fr) | 2017-07-26 | 2019-01-31 | F. Hoffmann-La Roche Ag | Polythérapie avec un inhibiteur bet, un inhibiteur bcl-2 et un anticorps anti-cd20 |
TW201920282A (zh) * | 2017-09-29 | 2019-06-01 | 中國大陸商上海藥明生物技術有限公司 | 抗egfr和pd-1的雙特異性抗體 |
EP3781139A1 (fr) | 2018-04-18 | 2021-02-24 | F. Hoffmann-La Roche AG | Polythérapie avec un inhibiteur de bet et un inhibiteur du protéasome |
WO2020234445A1 (fr) | 2019-05-23 | 2020-11-26 | F. Hoffmann-La Roche Ag | Polythérapie avec un inhibiteur de bet et un inhibiteur de bcl-2 |
WO2021155006A1 (fr) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040210A1 (fr) * | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Anticorps et fragments d'anticorps inhibant la croissance des tumeurs |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
-
1999
- 1999-05-14 PL PL99348634A patent/PL348634A1/xx unknown
- 1999-05-14 MX MXPA00011248A patent/MXPA00011248A/es unknown
- 1999-05-14 EP EP99924253A patent/EP1080113A4/fr not_active Withdrawn
- 1999-05-14 JP JP2000549641A patent/JP2002515511A/ja active Pending
- 1999-05-14 AU AU40799/99A patent/AU4079999A/en not_active Abandoned
- 1999-05-14 BR BR9910511-0A patent/BR9910511A/pt not_active Application Discontinuation
- 1999-05-14 WO PCT/US1999/010741 patent/WO1999060023A1/fr not_active Application Discontinuation
- 1999-05-14 SK SK1728-2000A patent/SK17282000A3/sk unknown
- 1999-05-14 CA CA002332331A patent/CA2332331A1/fr not_active Abandoned
- 1999-05-14 CN CN99808614A patent/CN1314917A/zh active Pending
- 1999-05-14 KR KR1020007012832A patent/KR20010071271A/ko not_active Application Discontinuation
- 1999-05-14 IL IL13970799A patent/IL139707A0/xx unknown
- 1999-05-14 CZ CZ20004224A patent/CZ20004224A3/cs unknown
-
2002
- 2002-03-18 HK HK02102068.1A patent/HK1040720A1/zh unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040210A1 (fr) * | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Anticorps et fragments d'anticorps inhibant la croissance des tumeurs |
Non-Patent Citations (5)
Title |
---|
BALABAN NAOMI ET AL: "The effect of ionizing radiation on signal transduction: Antibodies to EGF receptor sensitize A431 cells to radiation.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1314, no. 1-2, 1996, pages 147 - 156, XP001055207, ISSN: 0006-3002 * |
GOLDKORN T ET AL: "EGF receptor phosphorylation is affected by ionizing radiation", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1358, no. 3, 11 October 1997 (1997-10-11), pages 289 - 299, XP004277704, ISSN: 0167-4889 * |
SALEH M ET AL: "In vitro and in vivo evaluation of the cytotoxicity of radiation combined with chimeric monoclonal antibody to the epidermal growth factor receptor.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 37, 1996, 87th Annual Meeting of the American Association for Cancer Research;Washington, D.C., USA; April 20-24, 1996, 1996, pages 612, XP001027768, ISSN: 0197-016X * |
SALEH MANSOOR N ET AL: "Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation.", CANCER BIOTHERAPY & RADIOPHARMACEUTICALS, vol. 14, no. 6, 1999, pages 451 - 463, XP001027767, ISSN: 1084-9785 * |
See also references of WO9960023A1 * |
Also Published As
Publication number | Publication date |
---|---|
SK17282000A3 (sk) | 2002-04-04 |
CA2332331A1 (fr) | 1999-11-25 |
MXPA00011248A (es) | 2004-09-06 |
CN1314917A (zh) | 2001-09-26 |
EP1080113A1 (fr) | 2001-03-07 |
PL348634A1 (en) | 2002-06-03 |
BR9910511A (pt) | 2001-11-20 |
IL139707A0 (en) | 2002-02-10 |
AU4079999A (en) | 1999-12-06 |
HK1040720A1 (zh) | 2002-06-21 |
JP2002515511A (ja) | 2002-05-28 |
CZ20004224A3 (cs) | 2002-02-13 |
WO1999060023A1 (fr) | 1999-11-25 |
KR20010071271A (ko) | 2001-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL348634A1 (en) | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases | |
HUP0201480A3 (en) | Treatment of refractory human tumors with epidermal growth factor receptor antagonists | |
IL134013A (en) | Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors | |
EP1073496A4 (fr) | Catheter d'irradiation ameliore et procede d'utilisation | |
AU2002351397A1 (en) | Systems and methods using vasoconstriction for improved thermal treatment of tissues | |
HUP0203035A3 (en) | Compositions and methods for therapy and diagnosis of prostate cancer | |
DE60014581D1 (de) | Dynamische kühlung von hautgewebe zur strahlungsbehandlung | |
EP1097165A4 (fr) | Nouveaux inhibiteurs de l'angiogenese et de la croissance tumorale | |
PL352714A1 (en) | Diaminothiazoles and their use for inhibiting protein kinases | |
AU6528800A (en) | Methods and apparatuses for radiation treatment | |
IL126341A0 (en) | Radiation delivery devices and methods of making same | |
EP1169319A4 (fr) | Procedes et compositions permettant la degradation et/ou l'inhibition des tyrosine kinases appartenant a la famille her | |
HK1043113A1 (zh) | 端粒酶抑制劑及其使用方法 | |
DE60030164D1 (de) | 3-heteroarylidenyl-2-indolinon derivate mit protein kinase modulierender activity und zur verwendung in der krebschemotherapie | |
EP1175616A4 (fr) | Procedes pour le diagnostic et le traitement de tumeurs metastatiques de la prostate | |
PL352333A1 (en) | Dihydrobenzodiazepines and use of same in treatment of dislipidemia | |
EP1054979A4 (fr) | Compositions et procedes servant a sensibiliser et a inhiber la croissance de cellules cancereuses humaines | |
GB9811598D0 (en) | Diagnosis and treatment of cancer | |
HK1046915A1 (zh) | 人類肝細胞生長因子受體酪氨酸激酶催化結構域及鑒定其抑制劑的方法 | |
AU4492000A (en) | Determination of pacemaker wenckebach and adjustment of upper rate limit | |
EP1181374A4 (fr) | Nouvelles kinases humaines et murines | |
EP1161451A4 (fr) | Endokine alpha humain et methodes d'utilisation | |
AU8113401A (en) | Methods of treating cancer and the pain associated therewith using endothelin antagonists | |
NO20021430L (no) | Fremgangsmåte for terapeutisk forvaltning av ekstrauterin proliferering av endometrievev, kronisk bekkensmerte ogegglederobstruksjon | |
AU2002366230A1 (en) | Use of at least one abl, kit and/or platelet-derived growth factor receptor tyrosine kinases inhibitor for treating hair depigmentation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20001215 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BUCHSBAUM, DONALD, JAY Inventor name: ROBERT, FRANCISCO Inventor name: SALEH, MANSOOR, N. Inventor name: WAKSAL, HARLAN, W. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20020301 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7C 07K 16/00 A, 7A 61K 39/395 B, 7A 61N 5/10 B, 7C 07K 16/28 B |
|
TPAD | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOS TIPA |
|
17Q | First examination report despatched |
Effective date: 20030114 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050531 |